Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 277 to 282 of 282 entries
Sorted by: Best Match Show Resources per page
Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways.

Scientific reports

Hongo H, Kosaka T, Suzuki Y, Mikami S, Fukada J, Oya M.
PMID: 34782700
Sci Rep. 2021 Nov 15;11(1):22284. doi: 10.1038/s41598-021-01697-2.

Cabazitaxel (CBZ) is approved for the treatment of docetaxel-resistant castration-resistant prostate cancer (CRPC). However, its efficacy against CRPC is limited, and there are no effective treatments for CBZ-resistant CRPC. This study explored the optimal treatment for CRPC in the...

Cite
Hongo H, Kosaka T, Suzuki Y, et al. Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways. Sci Rep. 2021;11(1):22284doi: 10.1038/s41598-021-01697-2.
Hongo, H., Kosaka, T., Suzuki, Y., Mikami, S., Fukada, J., & Oya, M. (2021). Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways. Scientific reports, 11(1), 22284. https://doi.org/10.1038/s41598-021-01697-2
Hongo, Hiroshi, et al. "Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways." Scientific reports vol. 11,1 (2021): 22284. doi: https://doi.org/10.1038/s41598-021-01697-2
Hongo H, Kosaka T, Suzuki Y, Mikami S, Fukada J, Oya M. Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways. Sci Rep. 2021 Nov 15;11(1):22284. doi: 10.1038/s41598-021-01697-2. PMID: 34782700; PMCID: PMC8593019.
Copy Download .nbib Format: NLM
Microstructure and Fatigue Behaviors of Dissimilar A6061/Galvannealed Steel Joints Fabricated by Friction Stir Spot Welding.

Materials (Basel, Switzerland)

Kumamoto K, Kosaka T, Kobayashi T, Shohji I, Kamakoshi Y.
PMID: 34300794
Materials (Basel). 2021 Jul 12;14(14). doi: 10.3390/ma14143877.

The microstructures, tensile shear properties, and tensile shear fatigue properties of dissimilar A6061/Galvannealed steel joints fabricated by friction stir spot welding (FSSW) were investigated. Fe

Cite
Kumamoto K, Kosaka T, Kobayashi T, et al. Microstructure and Fatigue Behaviors of Dissimilar A6061/Galvannealed Steel Joints Fabricated by Friction Stir Spot Welding. Materials (Basel). 2021;14(14)doi: 10.3390/ma14143877.
Kumamoto, K., Kosaka, T., Kobayashi, T., Shohji, I., & Kamakoshi, Y. (2021). Microstructure and Fatigue Behaviors of Dissimilar A6061/Galvannealed Steel Joints Fabricated by Friction Stir Spot Welding. Materials (Basel, Switzerland), 14(14), . https://doi.org/10.3390/ma14143877
Kumamoto, Koki, et al. "Microstructure and Fatigue Behaviors of Dissimilar A6061/Galvannealed Steel Joints Fabricated by Friction Stir Spot Welding." Materials (Basel, Switzerland) vol. 14,14 (2021). doi: https://doi.org/10.3390/ma14143877
Kumamoto K, Kosaka T, Kobayashi T, Shohji I, Kamakoshi Y. Microstructure and Fatigue Behaviors of Dissimilar A6061/Galvannealed Steel Joints Fabricated by Friction Stir Spot Welding. Materials (Basel). 2021 Jul 12;14(14). doi: 10.3390/ma14143877. PMID: 34300794; PMCID: PMC8304940.
Copy Download .nbib Format: NLM
Lower Masticatory Performance Is a Risk for the Development of the Metabolic Syndrome: The Suita Study.

Frontiers in cardiovascular medicine

Fushida S, Kosaka T, Nakai M, Kida M, Nokubi T, Kokubo Y, Watanabe M, Miyamoto Y, Ono T, Ikebe K.
PMID: 34901213
Front Cardiovasc Med. 2021 Nov 26;8:752667. doi: 10.3389/fcvm.2021.752667. eCollection 2021.

No abstract available.

Cite
Fushida S, Kosaka T, Nakai M, et al. Lower Masticatory Performance Is a Risk for the Development of the Metabolic Syndrome: The Suita Study. Front Cardiovasc Med. 2021;8:752667doi: 10.3389/fcvm.2021.752667.
Fushida, S., Kosaka, T., Nakai, M., Kida, M., Nokubi, T., Kokubo, Y., Watanabe, M., Miyamoto, Y., Ono, T., & Ikebe, K. (2021). Lower Masticatory Performance Is a Risk for the Development of the Metabolic Syndrome: The Suita Study. Frontiers in cardiovascular medicine, 8752667. https://doi.org/10.3389/fcvm.2021.752667
Fushida, Shuri, et al. "Lower Masticatory Performance Is a Risk for the Development of the Metabolic Syndrome: The Suita Study." Frontiers in cardiovascular medicine vol. 8 (2021): 752667. doi: https://doi.org/10.3389/fcvm.2021.752667
Fushida S, Kosaka T, Nakai M, Kida M, Nokubi T, Kokubo Y, Watanabe M, Miyamoto Y, Ono T, Ikebe K. Lower Masticatory Performance Is a Risk for the Development of the Metabolic Syndrome: The Suita Study. Front Cardiovasc Med. 2021 Nov 26;8:752667. doi: 10.3389/fcvm.2021.752667. eCollection 2021. PMID: 34901213; PMCID: PMC8661002.
Copy Download .nbib Format: NLM
Real-World Therapeutic Outcomes of S-1 Adjuvant Chemotherapy for pStage II/III Gastric Cancer in the Elderly.

European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes

Kunisaki C, Sato S, Tsuchiya N, Kubo H, Watanabe J, Sato T, Takeda K, Tamura Y, Kasahara K, Kosaka T, Akiyama H, Endo I.
PMID: 33794520
Eur Surg Res. 2021;62(1):40-52. doi: 10.1159/000515175. Epub 2021 Apr 01.

BACKGROUND: The predictive factors for discontinuation of S-1 administration and prognostic factors in elderly patients with pStage II/III gastric cancer receiving S-1 adjuvant chemotherapy remain unclear.METHODS: Between January 2004 and December 2016, 80 elderly gastric cancer patients (≥70 years)...

Cite
Kunisaki C, Sato S, Tsuchiya N, et al. Real-World Therapeutic Outcomes of S-1 Adjuvant Chemotherapy for pStage II/III Gastric Cancer in the Elderly. Eur Surg Res. 2021;62(1):40-52doi: 10.1159/000515175.
Kunisaki, C., Sato, S., Tsuchiya, N., Kubo, H., Watanabe, J., Sato, T., Takeda, K., Tamura, Y., Kasahara, K., Kosaka, T., Akiyama, H., & Endo, I. (2021). Real-World Therapeutic Outcomes of S-1 Adjuvant Chemotherapy for pStage II/III Gastric Cancer in the Elderly. European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 62(1), 40-52. https://doi.org/10.1159/000515175
Kunisaki, Chikara, et al. "Real-World Therapeutic Outcomes of S-1 Adjuvant Chemotherapy for pStage II/III Gastric Cancer in the Elderly." European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes vol. 62,1 (2021): 40-52. doi: https://doi.org/10.1159/000515175
Kunisaki C, Sato S, Tsuchiya N, Kubo H, Watanabe J, Sato T, Takeda K, Tamura Y, Kasahara K, Kosaka T, Akiyama H, Endo I. Real-World Therapeutic Outcomes of S-1 Adjuvant Chemotherapy for pStage II/III Gastric Cancer in the Elderly. Eur Surg Res. 2021;62(1):40-52. doi: 10.1159/000515175. Epub 2021 Apr 01. PMID: 33794520.
Copy Download .nbib Format: NLM
Clinical characteristics, laboratory parameters and outcomes of COVID-19 in cancer and non-cancer patients from a tertiary Cancer Centre in India.

Cancer medicine

Mirgh SP, Gokarn A, Rajendra A, More A, Kamtalwar S, Katti KS, Singh A, Goli VB, Ravind R, Madala R, Kakoti S, Maitre P, Punatar S, Chichra A, Patil A, Trivedi B, Joshi A, Patkar N, Tembhare P, Khanka T, Rajpal S, Chatterjee G, Kannan S, Subramanian PG, Murthy V, Shetty N, Chavan P, Bhat V, Nair S, Khattry N, Gupta S.
PMID: 34786866
Cancer Med. 2021 Dec;10(24):8777-8788. doi: 10.1002/cam4.4379. Epub 2021 Nov 16.

BACKGROUND: There is paucity of data regarding clinical characteristics, laboratory parameters and outcomes of coronavirus disease (COVID-19) in cancer versus non-cancer patients, particularly from India.MATERIALS AND METHODS: This was an observational, single-centre, retrospective analysis of patients with laboratory-confirmed COVID-19...

Cite
Mirgh SP, Gokarn A, Rajendra A, et al. Clinical characteristics, laboratory parameters and outcomes of COVID-19 in cancer and non-cancer patients from a tertiary Cancer Centre in India. Cancer Med. 2021;10(24):8777-8788doi: 10.1002/cam4.4379.
Mirgh, S. P., Gokarn, A., Rajendra, A., More, A., Kamtalwar, S., Katti, K. S., Singh, A., Goli, V. B., Ravind, R., Madala, R., Kakoti, S., Maitre, P., Punatar, S., Chichra, A., Patil, A., Trivedi, B., Joshi, A., Patkar, N., Tembhare, P., Khanka, T., Rajpal, S., Chatterjee, G., Kannan, S., Subramanian, P. G., Murthy, V., Shetty, N., Chavan, P., Bhat, V., Nair, S., Khattry, N., & Gupta, S. (2021). Clinical characteristics, laboratory parameters and outcomes of COVID-19 in cancer and non-cancer patients from a tertiary Cancer Centre in India. Cancer medicine, 10(24), 8777-8788. https://doi.org/10.1002/cam4.4379
Mirgh, Sumeet P, et al. "Clinical characteristics, laboratory parameters and outcomes of COVID-19 in cancer and non-cancer patients from a tertiary Cancer Centre in India." Cancer medicine vol. 10,24 (2021): 8777-8788. doi: https://doi.org/10.1002/cam4.4379
Mirgh SP, Gokarn A, Rajendra A, More A, Kamtalwar S, Katti KS, Singh A, Goli VB, Ravind R, Madala R, Kakoti S, Maitre P, Punatar S, Chichra A, Patil A, Trivedi B, Joshi A, Patkar N, Tembhare P, Khanka T, Rajpal S, Chatterjee G, Kannan S, Subramanian PG, Murthy V, Shetty N, Chavan P, Bhat V, Nair S, Khattry N, Gupta S. Clinical characteristics, laboratory parameters and outcomes of COVID-19 in cancer and non-cancer patients from a tertiary Cancer Centre in India. Cancer Med. 2021 Dec;10(24):8777-8788. doi: 10.1002/cam4.4379. Epub 2021 Nov 16. PMID: 34786866; PMCID: PMC8646792.
Copy Download .nbib Format: NLM
Comprehensive expressional analysis of chemosensitivity-related markers in large cell neuroendocrine carcinoma of the lung.

Thoracic cancer

Ohtaki Y, Kaira K, Yajima T, Erkhem-Ochir B, Kawashima O, Kamiyoshihara M, Igai H, Onozato R, Ibe T, Kosaka T, Nakazawa S, Nagashima T, Oyama T, Shirabe K.
PMID: 34453496
Thorac Cancer. 2021 Oct;12(20):2666-2679. doi: 10.1111/1759-7714.14102. Epub 2021 Aug 28.

OBJECTIVES: Various drug-sensitivity markers have been reported to be associated with tumor progression and chemotherapy resistance. Detailed expression profiles of sensitivity markers for cytotoxic chemotherapy in pulmonary large cell neuroendocrine carcinoma (LCNEC) remain unclear. Herein, we aimed to clarify...

Cite
Ohtaki Y, Kaira K, Yajima T, et al. Comprehensive expressional analysis of chemosensitivity-related markers in large cell neuroendocrine carcinoma of the lung. Thorac Cancer. 2021;12(20):2666-2679doi: 10.1111/1759-7714.14102.
Ohtaki, Y., Kaira, K., Yajima, T., Erkhem-Ochir, B., Kawashima, O., Kamiyoshihara, M., Igai, H., Onozato, R., Ibe, T., Kosaka, T., Nakazawa, S., Nagashima, T., Oyama, T., & Shirabe, K. (2021). Comprehensive expressional analysis of chemosensitivity-related markers in large cell neuroendocrine carcinoma of the lung. Thoracic cancer, 12(20), 2666-2679. https://doi.org/10.1111/1759-7714.14102
Ohtaki, Yoichi, et al. "Comprehensive expressional analysis of chemosensitivity-related markers in large cell neuroendocrine carcinoma of the lung." Thoracic cancer vol. 12,20 (2021): 2666-2679. doi: https://doi.org/10.1111/1759-7714.14102
Ohtaki Y, Kaira K, Yajima T, Erkhem-Ochir B, Kawashima O, Kamiyoshihara M, Igai H, Onozato R, Ibe T, Kosaka T, Nakazawa S, Nagashima T, Oyama T, Shirabe K. Comprehensive expressional analysis of chemosensitivity-related markers in large cell neuroendocrine carcinoma of the lung. Thorac Cancer. 2021 Oct;12(20):2666-2679. doi: 10.1111/1759-7714.14102. Epub 2021 Aug 28. PMID: 34453496; PMCID: PMC8520808.
Copy Download .nbib Format: NLM
Showing 277 to 282 of 282 entries